1-13 of 13
Uli C. Broedl
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

Nikolaus Marx, Darren K. McGuire, Vlado Perkovic, Hans-Juergen Woerle, Uli C. Broedl, Maximilian von Eynatten, Jyothis T. George, Julio Rosenstock
Journal: Diabetes Care
Diabetes Care 2017;40(9):1144–1151
https://doi.org/10.2337/dc17-0068
Published: 14 August 2017
View articletitled, Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
Open the PDF for Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point? in another window
Journal Articles

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

Eirik Søfteland, Juris J. Meier, Bente Vangen, Robert Toorawa, Mario Maldonado-Lutomirsky, Uli C. Broedl
Journal: Diabetes Care
Diabetes Care 2017;40(2):201–209
https://doi.org/10.2337/dc16-1347
Published: 02 December 2016
View articletitled, Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial
Open the PDF for Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial in another window
Includes: Supplementary data
Journal Articles

Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes

Samy Hadjadj, Julio Rosenstock, Thomas Meinicke, Hans J. Woerle, Uli C. Broedl
Journal: Diabetes Care
Diabetes Care 2016;39(10):1718–1728
https://doi.org/10.2337/dc16-0522
Published: 04 August 2016
View articletitled, Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes
Open the PDF for Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Erratum. Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin. Diabetes Care 2015;38: 384–393

Ralph A. DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J. Woerle, Uli C. Broedl
Journal: Diabetes Care
Diabetes Care 2015;38(6):1173
https://doi.org/10.2337/dc15-er06
Published: 12 May 2015
View articletitled, Erratum. Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin. Diabetes Care 2015;38: 384–393
Open the PDF for Erratum. Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin. Diabetes Care 2015;38: 384–393 in another window
Journal Articles

Erratum. Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes. Diabetes Care 2015;38: 394–402

Andrew Lewin, Ralph A. DeFronzo, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J. Woerle, Uli C. Broedl
Journal: Diabetes Care
Diabetes Care 2015;38(6):1173
https://doi.org/10.2337/dc15-er06a
Published: 12 May 2015
View articletitled, Erratum. Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes. Diabetes Care 2015;38: 394–402
Open the PDF for Erratum. Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes. Diabetes Care 2015;38: 394–402 in another window
Journal Articles

Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes

Andrew Lewin, Ralph A. DeFronzo, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J. Woerle, Uli C. Broedl
Journal: Diabetes Care
Diabetes Care 2015;38(3):394–402
https://doi.org/10.2337/dc14-2365
Published: 29 January 2015
View articletitled, Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
Open the PDF for Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin

Ralph A. DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J. Woerle, Uli C. Broedl
Journal: Diabetes Care
Diabetes Care 2015;38(3):384–393
https://doi.org/10.2337/dc14-2364
Published: 12 January 2015
View articletitled, Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
Open the PDF for Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin in another window
Includes: Supplementary data
Journal Articles

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C. Broedl, Hans J. Woerle
Journal: Diabetes Care
Diabetes Care 2015;38(3):420–428
https://doi.org/10.2337/dc14-1096
Published: 30 September 2014
View articletitled, Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Open the PDF for Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension in another window
Includes: Supplementary data
Journal Articles

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

Julio Rosenstock, Ante Jelaska, Guillaume Frappin, Afshin Salsali, Gabriel Kim, Hans J. Woerle, Uli C. Broedl
Journal: Diabetes Care
Diabetes Care 2014;37(7):1815–1823
https://doi.org/10.2337/dc13-3055
Published: 12 June 2014
View articletitled, Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
Open the PDF for Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C. Broedl, Hans J. Woerle, on behalf of the EMPA-REG MET Trial Investigators
Journal: Diabetes Care
Diabetes Care 2014;37(6):1650–1659
https://doi.org/10.2337/dc13-2105
Published: 10 May 2014
View articletitled, Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Open the PDF for Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial in another window
Includes: Supplementary data
Journal Articles

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

Bruce A. Perkins, David Z.I. Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M. Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C. Broedl, Odd-Erik Johansen
Journal: Diabetes Care
Diabetes Care 2014;37(5):1480–1483
https://doi.org/10.2337/dc13-2338
Published: 10 April 2014
View articletitled, Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial
Open the PDF for Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial in another window
Includes: Supplementary data
Journal Articles

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

Ele Ferrannini, MD, Andreas Berk, PHD, Stefan Hantel, PHD, Sabine Pinnetti, MD, Thomas Hach, MD, Hans J. Woerle, MD, Uli C. Broedl, MD
Journal: Diabetes Care
Diabetes Care 2013;36(12):4015–4021
https://doi.org/10.2337/dc13-0663
Published: 13 November 2013
View articletitled, Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
Open the PDF for Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes in another window
Includes: Supplementary data
Journal Articles

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

Hans-Ulrich Häring, MD, Ludwig Merker, MD, Elke Seewaldt-Becker, PHD, Marc Weimer, PHD, Thomas Meinicke, MD, Hans J. Woerle, MD, Uli C. Broedl, MD, on behalf of the EMPA-REG METSU Trial Investigators
Journal: Diabetes Care
Diabetes Care 2013;36(11):3396–3404
https://doi.org/10.2337/dc12-2673
Published: 15 October 2013
View articletitled, Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
Open the PDF for Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial in another window
Includes: Supplementary data